Lustgarten, Stephanie

Initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC).

Banerjee, S. N., Ring, K. L., Van Nieuwenhuysen, E., Fabbro, M., Aghajanian, C., Oaknin, A., Colombo, N., Santin, A., Clamp, A. R., Moore, K. N., et al. (2023) · Journal of Clinical Oncology

Ovarian cancer diagnosis and treatmentOvarian function and disorders

Cited by 38

Abstract 3476: Mechanistic evaluation of VS-6766 (dual RAF/MEK inhibitor) and defactinib (FAK inhibitor) in low-grade serous ovarian cancer models with correlations to clinical response

Stewart, A. R., Pickard, L., Paranjape, E., Perez, V. S., Chowdhury, S., Lustgarten, S., Coma, S., Pachter, J. A., Carey, M. S., DiMattia, G., et al. (2022) · Cancer Research

Ovarian cancer diagnosis and treatmentMelanoma and MAPK Pathways

Cited by 1